Growth through acquisitions Ergomed’s recent acquisitions and Permira-backed growth position the company as a broader end-to-end CRO with increased capacity and global reach. This creates sales opportunities to pitch expanded services including pharmacovigilance, project management, and late-stage trial execution to sponsors seeking scale and single-vendor convenience.

Therapeutic depth A proven oncology focus with substantial experience in neurology/CNS and infectious diseases provides a strong competitive angle for sponsors prioritizing oncology and complex patient populations. Use the track record of 795+ trials and 250+ oncology studies to support win-ready case studies and proposals.

Global network With operations across more than 100 countries after recent acquisitions, Ergomed offers true global reach and regulatory alignment, enabling faster site activation and adaptive trial design for multinational studies.

Relationship value The emphasis on strong relationships, transparency, and flexible processes resonates with sponsors seeking dependable trial partners who minimize risk and maintain open communication throughout the study lifecycle.

Integrated tech Post-acquisition integration creates cross-functional offerings across pharmacovigilance, project management, and trial operations, supported by collaboration tools and a modern tech stack, enabling efficient remote monitoring, data sharing, and faster decision-making in trials.